Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic Disorders

Shekhar, Skand; Copacino, Caroline E; Barrera, Francisco J.; Hall, Janet E.; Hannah‐Shmouni, Fady

doi:10.1055/s-0040-1713346

Cited by 1 publication

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a link between higher DPP4 activity and expression and metabolic syndrome (MS) and obesity. [159][160][161][162] This suggests a direct metabolic and endocrine relationship to the viral pathogenesis, emphasizing the need for proper treatment in COVID-19 patients with these comorbidities. 163 DPP4 is believed to be a co-receptor for the entrance of the SARS-CoV-2 virus and as DPP4 dysregulation is associated with disease severity in COVID-19, it is important to learn more about how DPP4 inhibition affects the course of the illness.…”

Section: Covid-19 Comorbidities Disease Manifestations and Severitymentioning

confidence: 99%

Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors

Rahim,

Shan,

Ul Haq

et al. 2024

JIR

View full text Add to dashboard Cite

DPP4 (Dipeptidyl-peptidase 4) a versatile protease, emerges as a prominent player in soluble and membrane-bound forms. Its heightened expression has been intimately linked to the initiation and severity of diverse autoimmune diseases, spanning rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (SSc), inflammatory bowel disease, autoimmune diabetes, and even SARS-CoV-2 infection. Operating as a co-stimulator of T cell activity, DPP4 propels T cell proliferation by binding adenosine deaminase (ADA), thereby augmenting the breakdown of adenosine—an influential inhibitor of T cell proliferation. However, the discovery of a wide range of DPP4 inhibitors has shown promise in alleviating these diseases’ signs, symptoms, and severity. The available DPP4 inhibitors have demonstrated significant effectiveness in blocking DPP4 activity. Based on the characterization of their binding mechanisms, three distinct groups of DPP4 inhibitors have been identified: saxagliptin, alogliptin, and sitagliptin, each representing a different class. Elevated levels of angiotensin-converting enzyme 2 (ACE2) expression are associated with producing various coronavirus peptidases. With its anti-inflammatory properties, Sitagliptin may assist COVID-19 patients in preventing and managing cytokine storms. This comprehensive review delves into the burgeoning realm of DPP4 inhibitors as therapeutic interventions for diverse autoimmune diseases. With a discerning focus on their efficacy, the investigation sheds light on their remarkable capacity to alleviate the burdensome signs and symptoms intricately linked to these conditions.

show abstract

Section: Covid-19 Comorbidities Disease Manifestations and Severitymentioning

confidence: 99%

Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors

Rahim,

Shan,

Ul Haq

et al. 2024

JIR

View full text Add to dashboard Cite

show abstract

Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic Disorders

Cited by 1 publication

References 38 publications

Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors

Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors

Contact Info

Product

Resources

About